Accuray Incorporated reported a significant decline in its financial performance for the second quarter of fiscal year 2026, ending December 31, 2025. The company recorded total net revenue of $102.2 million, a decrease of 12% from $116.2 million in the same quarter of the previous year. For the six-month period, revenue fell by 10% to $196.2 million compared to $217.7 million in the prior year. The decline was primarily attributed to a 26% drop in product revenue, which totaled $45.0 million, while service revenue increased by 4% to $57.2 million, reflecting a growing installed base and higher contract revenues.
The company's gross profit also suffered, decreasing to $24.1 million for the quarter, down 43% from $41.9 million a year earlier. This decline was driven by reduced product unit sales and a less favorable product mix. Operating expenses remained relatively stable at $35.6 million, with restructuring costs of $6.1 million included as part of the FY26 Restructuring Plan, which aims to streamline operations and reduce costs. The net loss for the quarter was $13.8 million, compared to a net income of $2.5 million in the prior year, resulting in a loss per share of $0.11.
In terms of operational developments, Accuray's restructuring plan involved a workforce reduction of approximately 15% during the quarter, aimed at improving efficiency and reducing costs. The company also reported a decrease in its customer base, with significant impacts from geopolitical and macroeconomic factors, including inflation and supply chain challenges. The company’s joint venture in China, which previously contributed significantly to revenue, saw a 51% decline in sales, reflecting ongoing market challenges.
Looking ahead, Accuray anticipates continued pressure on its financial performance due to external factors such as inflation, supply chain disruptions, and reduced capital deployment priorities for radiotherapy equipment. The company expects these challenges to persist through at least fiscal year 2026. Despite these headwinds, Accuray believes it has sufficient cash resources and anticipated cash flows to fund operations for the next 12 months, although it remains cautious about the potential impacts of ongoing geopolitical tensions and economic conditions on its business.
About ACCURAY INC
Accuray Incorporated is a radiation therapy company specializing in advanced treatment solutions for cancer and other disorders. Its key products, including the CyberKnife and TomoTherapy platforms, utilize innovative technologies like AI-driven motion tracking for precise, personalized treatments. With a focus on enhancing patient care and expanding market reach, Accuray targets healthcare providers globally, aiming to improve treatment efficiency and outcomes while addressing significant unmet needs in oncology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.